Ratings by William Blair (Tim Lugo)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/15/2024 | Eyenovia | EYEN | Downgrade | Market Perform (Outperform) |
0.34 (1.65) |
385.29% | Details | |
| 8/12/2024 | Revance Therapeutic | RVNC | Downgrade | Market Perform (Outperform) |
3.53 (3.65) |
3.4% | Details | |
| 7/31/2024 | Applied Therapeutics | APLT | New Coverage | Outperform (N/A) |
4.98 (0.88) |
-82.33% | Details | |
| 7/26/2024 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 7/9/2024 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/28/2024 | Travere Therapeutics | TVTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/13/2024 | Revance Therapeutic | RVNC | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2024 | Lyra Therapeutics | LYRA | Downgrade | Market Perform (Outperform) |
4.03 (0.17) |
-95.78% | Details | |
| 4/17/2024 | Sage Therapeutics | SAGE | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/15/2024 | LENZ Therapeutics Inc | LENZ | New Coverage | Outperform (N/A) |
21.89 (25.45) |
16.26% | Details | |
| 3/28/2024 | Solid Biosciences | SLDB | New Coverage | Outperform (N/A) |
14.25 (5.09) |
-64.28% | Details | |
| 3/12/2024 | Zevra Therapeutics, Inc. | ZVRA | New Coverage | Outperform (N/A) |
6.13 (8.31) |
35.56% | Details | |
| 2/20/2024 | ARS Pharmaceuticals Inc | SPRY | Upgrade | Outperform (Market Perform) |
7.17 (11.87) |
65.55% | Details | |
| 2/16/2024 | Kinnate Biopharma | KNTE | Downgrade | Market Perform (Outperform) |
2.27 (2.65) |
16.74% | Details | |
| 1/29/2024 | Abbvie | ABBV | Upgrade | Outperform (Market Perform) |
164.40 (211.77) |
28.81% | Details | |
| 12/20/2023 | argenx SE | ARGX | Downgrade | Market Perform (Outperform) |
452.58 (551.71) |
21.9% | Details | |
| 12/18/2023 | Allakos Inc. | ALLK | Upgrade | Outperform (Market Perform) |
3.00 (0.25) |
-91.67% | Details | |
| 11/13/2023 | Aclaris Therapeutis | ACRS | Downgrade | Market Perform (Outperform) |
4.76 (1.56) |
-67.23% | Details | |
| 11/1/2023 | Eyenovia | EYEN | New Coverage | Outperform (N/A) |
1.30 (1.65) |
26.92% | Details | |
| 9/21/2023 | Travere Therapeutics | TVTX | Downgrade | Market Perform (Outperform) |
12.88 (19.73) |
53.18% | Details | |
| 9/20/2023 | ARS Pharmaceuticals Inc | SPRY | Downgrade | Market Perform (Outperform) |
7.44 (11.87) |
59.54% | Details | |
| 7/25/2023 | Abbvie | ABBV | New Coverage | Market Perform (N/A) |
143.18 (211.77) |
47.9% | Details | |
| 5/24/2023 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2023 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 1/3/2023 | ARS Pharmaceuticals Inc | SPRY | New Coverage | Outperform (N/A) |
8.53 (11.87) |
39.16% | Details | |
| 9/9/2022 | Allakos Inc. | ALLK | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/8/2022 | Revance Therapeutic | RVNC | Maintain | Outperform (N/A) |
|
Details | ||
| 8/3/2022 | Sarepta Therapeutics | SRPT | Maintain | Outperform (Outperform) |
|
Details | ||
| 7/22/2022 | VistaGen Therapeutics | VTGN | Downgrade | Market Perform (Outperform) |
1.07 (2.70) |
152.34% | Details | |
| 7/22/2022 | VistaGen Therapeutics | VTGN | Downgrade | Market Perform (Outperform) |
1.07 (1.07) |
0% | Details | |
| 7/13/2022 | Xenon Pharmaceuticals | XENE | Maintain | Outperform (Outperform) |
|
Details | ||
| 7/13/2022 | 9 Meter Biopharma | NMTR | Maintain | Outperform (Outperform) |
|
Details | ||
| 7/13/2022 | VistaGen Therapeutics | VTGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/24/2022 | Sarepta Therapeutics | SRPT | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/23/2022 | Xenon Pharmaceuticals | XENE | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/8/2022 | VistaGen Therapeutics | VTGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/8/2022 | Albireo Pharma | ALBO | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/26/2022 | VistaGen Therapeutics | VTGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/23/2022 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/4/2022 | Brickell Biotech Inc. | BBI | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/5/2022 | Collegium Pharmaceutical | COLL | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/4/2022 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/29/2022 | Kinnate Biopharma | KNTE | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/28/2022 | Eagle Pharmaceuticals | EGRX | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/23/2022 | 9 Meter Biopharma | NMTR | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/15/2022 | Brickell Biotech Inc. | BBI | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/9/2022 | Lyra Therapeutics | LYRA | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/8/2022 | Revance Therapeutic | RVNC | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/8/2022 | Brickell Biotech Inc. | BBI | New Coverage | Outperform (N/A) |
0.20 (2.35) |
1075% | Details | |
| 3/2/2022 | Allakos Inc. | ALLK | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 3/1/2022 | Albireo Pharma | ALBO | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/25/2022 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/16/2022 | Allakos Inc. | ALLK | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 2/11/2022 | VistaGen Therapeutics | VTGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/19/2022 | Zogenix, Inc. | ZGNX | Downgrade | Market Perform (Outperform) |
15.64 (26.68) |
70.59% | Details | |
| 1/19/2022 | Revance Therapeutic | RVNC | Maintain | Outperform (Outperform) |
|
Details | ||
| 12/22/2021 | Allakos Inc. | ALLK | Downgrade | Market Perform (Outperform) |
84.39 (0.25) |
-99.7% | Details | |
| 11/9/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/19/2021 | Atea Pharmaceuticals | AVIR | Maintain | Outperform (N/A) |
|
Details | ||
| 10/11/2021 | Adamas Pharmaceuticals | ADMS | Downgrade | Market Perform (Outperform) |
4.61 (8.22) |
78.31% | Details | |
| 8/31/2021 | Eagle Pharmaceuticals | EGRX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/13/2021 | Kinnate Biopharma | KNTE | New Coverage | Outperform (N/A) |
22.61 (2.27) |
-89.96% | Details | |
| 6/15/2021 | Sage Therapeutics | SAGE | Downgrade | Market Perform (Outperform) |
72.86 (7.72) |
-89.4% | Details | |
| 1/4/2021 | VistaGen Therapeutics | VTGN | Upgrade | Outperform (Market Perform) |
1.94 (2.70) |
39.18% | Details | |
| 11/24/2020 | Atea Pharmaceuticals | AVIR | New Coverage | Outperform (N/A) |
33.54 (3.08) |
-90.82% | Details | |
| 9/23/2020 | 9 Meter Biopharma | NMTR | New Coverage | Outperform (N/A) |
0.69 (0.07) |
-89.86% | Details | |
| 6/26/2020 | Zogenix, Inc. | ZGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/5/2020 | Adamas Pharmaceuticals | ADMS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2020 | BVHN | Maintain | Outperform (N/A) |
|
Details | |||
| 5/26/2020 | Lyra Therapeutics | LYRA | New Coverage | Outperform (N/A) |
14.43 (4.03) |
-72.07% | Details | |
| 2/3/2020 | Agile Therapeutics | AGRX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/8/2020 | Xenon Pharmaceuticals | XENE | New Coverage | Outperform (N/A) |
14.73 (35.32) |
139.78% | Details | |
| 12/10/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/14/2019 | VistaGen Therapeutics | VTGN | Downgrade | Market Perform (Outperform) |
1.08 (2.70) |
150% | Details | |
| 10/31/2019 | argenx SE | ARGX | Upgrade | Outperform (Market Perform) |
119.14 (604.96) |
407.77% | Details | |
| 9/17/2019 | Collegium Pharmaceutical | COLL | Maintain | Outperform (N/A) |
|
Details | ||
| 8/28/2019 | VistaGen Therapeutics | VTGN | New Coverage | Outperform (N/A) |
0.64 (1.08) |
68.75% | Details | |
| 6/25/2019 | Acer Therapeutics | ACER | Downgrade | Market Perform (Outperform) |
19.28 (0.90) |
-95.33% | Details | |
| 12/20/2018 | Shire | SHPG | Downgrade | Market Perform (Outperform) |
168.73 (179.20) |
6.21% | Details | |
| 8/13/2018 | Allakos Inc. | ALLK | New Coverage | Outperform (N/A) |
37.27 (0.25) |
-99.33% | Details |
